Finerenone

Finerenone

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
Synonyms	BAY 94-8862
CAS Number	1050477-31-0
PubChem CID	60150535
ChemSpider	28669387
UNII	DE2O63YV8R
KEGG	D10633
ChEMBL	CHEMBL2181927
Chemical and physical data
Formula	C21H22N4O3
Molar mass	378.42 g/mol
3D model (Jmol)	Interactive image
SMILES CCOc1c2c(c(cn1)C)NC(=C([C@H]2c3ccc(cc3OC)C#N)C(=O)N)C
InChI InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1 Key:BTBHLEZXCOBLCY-QGZVFWFLSA-N

Finerenone (INN, USAN) (developmental code name BAY-94-8862) is a non-steroidal antimineralocorticoid that is in phase III clinical trials for the treatment of chronic heart failure as of October 2015^[update]. It has less relative affinity to other steroid hormone receptors than currently available antimineralocorticoids such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low sex drive.

Finerenone blocks mineralocorticoid receptors, which makes it a potassium-sparing diuretic.

This table compares inhibitory (blocking) concentrations (IC₅₀, unit: nM) of three antimineralocorticoids. Mineralocorticoid receptor inhibition is responsible for the desired action of the drugs, whereas inhibition of the other receptors potentially leads to side effects. Lower values mean stronger inhibition.

The above-listed drugs have insignificant affinity for the estrogen receptor.